Interleukin-33 and receptor ST2 as indicators in patients with asthma: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 14935-14943

  Li, Rui ^a   Yang, Gang ^a   Yang, Ruiqi ^b   Peng, Xiaoxing ^a   Li, Jing ^a  

^a CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Asthma; Interleukin 33; Meta analysis; ST2

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN RECEPTOR; INTERLEUKIN RECEPTOR ST 2; UNCLASSIFIED DRUG;

ASTHMA; DISEASE COURSE; DISEASE SEVERITY; EOSINOPHIL; HEALTH STATUS INDICATOR; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW;

EID: 84946568066     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Masoli M, Fabian D, Holt S. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-78.
2. Zhu S, Chan-Yeung M, Becker AB, Dimich-Ward H, Ferguson AC, Manfreda J, Watson WT, Paré PD, Sandford AJ. Polymorphisms of the IL-4, TNF-alpha, and Fcepsilon RIbeta genes and the risk of allergic disorders in at-risk infants. Am J Respir Crit Care Med 2000; 161: 1655-9.
3. Gold DR. Environmental tobacco smoke, indoor allergens, and childhood asthma. Environ Health Perspect 2000; 108: 643-51.
4. Borish L, Steinke JW. Interleukin-33 in asthma: how big of a role does it play? Curr Allergy Asthma Rep 2011; 11: 7-11.
5. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces Thelper type 2-associated cytokines. Immunity 2005; 23: 479-90.
6. Löhning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, Kamradt T. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998; 95: 6930-5.
7. Kakkar R and Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7: 827-40.
8. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8: 22.
9. Tjota MY, Williams JW, Lu T, Clay BS, Byrd T, Hrusch CL, Decker DC, de Araujo CA, Bryce PJ, Sperling AI. IL-33-dependent induction of allergic lung inflammation by FcγRIII signaling. J Clin Invest 2013; 123: 2287-97.
10. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, Tominaga SI, Sugiyama Y. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164: 277-81.
11. Azazi EA, Berraies A, Kaabachi W, Haifa M, Ammar J, Kamel H. Serum levels of Interleukin-33 and its soluble receptor ST2 in asthmatic patients. Egyptian Journal of Chest Diseases and Tuberculosis 2013.
12. Liu SP, Ma R, Li XA. The relationship between interleukin 33 promotes and lung inflammation in asthmatic children. Chin J Diffic and Compl Cas 2013; 12: 422-4.
13. Zhang XL. Study on the correlation between the levels of IL-18, IL-33 and other inflammatory factors and pulmonary function in different stages of asthma. Dalian Medical University 2011; Master Thesis.
14. Yang DX. Effect of Glucocorticoid Treatment on the Levels of Serum IL-18 and IL-33 in Asthmatic Patients. Dalian Medical University 2011; Master Thesis.
15. Préfontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, Martin JG, Hamid Q. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010; 125: 752-4.
16. Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemière C, Martin JG, Hamid Q. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183: 5094-103.
17. Hamzaoui A, Berraies A, Kaabachi W, Haifa M, Ammar J, Kamel H. Induced sputum levels of IL-33 and soluble ST2 in young asthmatic children. J Asthma 2013; 50: 803-9.
18. Liao XM. Changes of plasma interleukin 33 in asthmatic patients and its clinical significance. Journal of Clinical Pulmonary Medicine 2014; 19: 33-5.
19. Li YM, Cheng XM. Clinical significance of IL-18 and IL-33 levels changes in the treatment of bronchial asthma with acute attack stage by glucocorticoids. Practical Pharmacy and Clinical Remedies 2013; 16: 897-9.
20. Ma XY, Luo YL, Lai WY. IL-33 levels in peripheral blood plasma and sputum of patients with bronchial asthma and their correlation with symptoms of patients, pulmonary function, and eosinophil numbers. J Third Mil Med Univ 2011; 33: 1526-9.
21. Gong ZJ, Li WY, Chen GH. A study on ST2 as a marker for Th2 cells and its relation to bronchial asthma. Shanghai Journal of Immunology 2002; 22: 82-5.
22. Zhang HQ, Wu LF, Sun ZL. Serum levels of IL33 and IL5 in patients with allergic rhinitis and bronchial asthma. Journal of Zhejiang Medicine 2013; 35: 1755-6.
23. Li QY, Huang XX, Zhang HY. Significance of changes of serum interleuin in patient with acute attack of bronchial asthma. China Medicine 2013; 8: 1556-7.
24. Chu MA, Lee JH, Lee EJ. Increased serum soluble ST2 in asthmatic children and recurrent early wheezers. Allergy Asthma Respir Dis 2013; 1: 314-20.
25. Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res 2012; 61: 547-50.
26. Arshad MI, Piquet-Pellorce C, Samson M. IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int 2012; 32: 1200-10.
27. Roy A, Ganesh G, Sippola H, Bolin S, Sawesi O, Dagälv A, Schlenner SM, Feyerabend T, Rodewald HR, Kjellén L, Hellman L, Åbrink M. Mast Cell Chymase Degrades the Alarmins Heat Shock Protein 70, Biglycan, HMGB1, and Interleukin-33 (IL-33) and Limits Dangerinduced Inflammation. J Biol Chem 2014; 289: 237-50.
28. Lopetuso LR, Scaldaferri F, Pizarro TT. Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 2012; 5: 18.
29. Lécart S, Lecointe N, Subramaniam A, Alkan S, Ni D, Chen R, Boulay V, Pène J, Kuroiwa K, Tominaga S, Yssel H. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002; 32: 2979-87.
30. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181: 788-96.
31. Savenije OE, Kerkhof M, Reijmerink NE, Brunekreef B, de Jongste JC, Smit HA, Wijga AH, Postma DS, Koppelman GH. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J Allergy Clin Immunol 2011; 127: 750-6.
32. Ali M, Zhang G, Thomas WR, McLean CJ, Bizzintino JA, Laing IA, Martin AC, Goldblatt J, Le Souëf PN, Hayden CM. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 2009; 73: 206-12.
33. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538-49.